Results 111 to 120 of about 6,619 (182)

Long-term safety profile of tolvaptan in autosomal dominant polycystic kidney disease patients: TEMPO Extension Japan Trial [Corrigendum]

open access: yes, 2018
Muto S, Okada T, Yasuda M, et al. Drug Healthc Patient Saf. 2017;9:93–104.On page 97, ‘Discussion’ section, lines 10–13, left column, the sentence: ‘Similarly, placebo patients who crossed over onto active treatment ...
Nakajima K   +5 more
core  

MEDA-PKD: a dynamic, real-time analytics platform for precision care in autosomal dominant polycystic kidney disease. [PDF]

open access: yesNPJ Digit Med
Grundmann F   +24 more
europepmc   +1 more source

Clinical Trial of Tolvaptan in Pediatric ADPKD: Two-Year, Open-Label Extension. [PDF]

open access: yesKidney Int Rep
Mekahli D   +12 more
europepmc   +1 more source

Short-term effects of an SGLT2 inhibitor on divalent ions in autosomal dominant polycystic kidney disease: a randomized crossover trial. [PDF]

open access: yesClin Kidney J
Roth L   +8 more
europepmc   +1 more source

Long-term safety profile of tolvaptan in autosomal dominant polycystic kidney disease patients: TEMPO Extension Japan Trial

open access: yes, 2017
Satoru Muto,1 Tadashi Okada,2 Moriyoshi Yasuda,3 Hidetsugu Tsubouchi,4 Koji Nakajima,4 Shigeo Horie1,5 1Department of Advanced Informatics for Genetic Disease, Juntendo University Graduate School of Medicine, Tokyo, 2Department of Clinical Development ...
Nakajima K   +5 more
core  

Vaptans: A Narrative Review of Pharmacokinetics, Pharmacogenetics, and Clinical Applications. [PDF]

open access: yesCells
Lica-Miler M   +6 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy